EA201791882A1 - Агонисты 5ht для лечения нарушений - Google Patents

Агонисты 5ht для лечения нарушений

Info

Publication number
EA201791882A1
EA201791882A1 EA201791882A EA201791882A EA201791882A1 EA 201791882 A1 EA201791882 A1 EA 201791882A1 EA 201791882 A EA201791882 A EA 201791882A EA 201791882 A EA201791882 A EA 201791882A EA 201791882 A1 EA201791882 A1 EA 201791882A1
Authority
EA
Eurasian Patent Office
Prior art keywords
violations
agonists
treatment
envisaged
treating
Prior art date
Application number
EA201791882A
Other languages
English (en)
Inventor
Скотт К. Барабан
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа
Publication of EA201791882A1 publication Critical patent/EA201791882A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предусматриваются, среди прочего, способы лечения эпилептического расстройства с использованием агониста рецептора 5НТ или его фармацевтически приемлемой соли.
EA201791882A 2015-02-25 2016-02-24 Агонисты 5ht для лечения нарушений EA201791882A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562120726P 2015-02-25 2015-02-25
PCT/US2016/019368 WO2016138138A1 (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders

Publications (1)

Publication Number Publication Date
EA201791882A1 true EA201791882A1 (ru) 2018-02-28

Family

ID=56789223

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201992474A EA201992474A3 (ru) 2015-02-25 2016-02-24 Агонисты 5ht для лечения нарушений
EA201791882A EA201791882A1 (ru) 2015-02-25 2016-02-24 Агонисты 5ht для лечения нарушений

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201992474A EA201992474A3 (ru) 2015-02-25 2016-02-24 Агонисты 5ht для лечения нарушений

Country Status (19)

Country Link
US (4) US10874643B2 (ru)
EP (3) EP4043016A1 (ru)
JP (5) JP6884703B2 (ru)
KR (3) KR20230152844A (ru)
CN (2) CN107530326B (ru)
AU (3) AU2016222804C1 (ru)
BR (1) BR112017018297B1 (ru)
CA (2) CA3204599A1 (ru)
DK (1) DK3261640T3 (ru)
EA (2) EA201992474A3 (ru)
ES (1) ES2920886T3 (ru)
HR (1) HRP20220822T1 (ru)
HU (1) HUE059559T2 (ru)
LT (1) LT3261640T (ru)
PL (1) PL3261640T3 (ru)
PT (1) PT3261640T (ru)
RS (1) RS63426B1 (ru)
SI (1) SI3261640T1 (ru)
WO (1) WO2016138138A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
CN108883399B (zh) 2015-12-22 2021-06-22 周格尼克斯国际有限公司 芬氟拉明组合物及其制备方法
CA3007673A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
JP7236389B2 (ja) 2016-12-20 2023-03-09 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンを含有する経皮治療システム
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
CR20210095A (es) * 2018-07-27 2021-06-01 Xenon Pharmaceuticals Inc Metodo para tratar la epilepsia
US20220226508A1 (en) * 2019-05-29 2022-07-21 The Regents Of The University Of California Methods and compositions for treating epilepsy
EP3791873A1 (en) * 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
EP4048249A4 (en) * 2019-10-23 2023-12-13 MapLight Therapeutics, Inc. METHOD FOR TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER
KR20210054684A (ko) 2019-11-06 2021-05-14 동국대학교 경주캠퍼스 산학협력단 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
MX2022006014A (es) * 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
KR102476771B1 (ko) * 2020-05-08 2022-12-13 광운대학교 산학협력단 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
IL307194A (en) * 2021-03-25 2023-11-01 Maplight Therapeutics Inc Pharmaceutical preparations containing zolmitriptan
CA3221934A1 (en) * 2021-06-01 2022-12-08 Arena Pharmaceuticals, Inc. Methods of treatment
CN117580579A (zh) * 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物
KR20240042485A (ko) * 2021-07-30 2024-04-02 에피제닉스 테라퓨틱스, 인크. 클레미졸 제제
WO2023107965A1 (en) * 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc)
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
US11974992B2 (en) 2022-01-26 2024-05-07 Neurolixis Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023212244A1 (en) * 2022-04-27 2023-11-02 Tessellate Therapeutics, Inc. Methods of treating 5ht2a receptor-mediated conditions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
WO2002089731A2 (en) 2001-05-03 2002-11-14 Stanford University Agents for treatment of hcv and methods of use
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
WO2005032329A2 (en) 2003-08-22 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-hcv agents
US20050215589A1 (en) 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
WO2008036586A2 (en) 2006-09-20 2008-03-27 Waters Investments Limited Apparatus and methods of fluid chromatography
CN101652259B (zh) 2007-04-06 2012-07-11 皇家飞利浦电子股份有限公司 空气污染传感器系统
TW200848063A (en) 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
US20110009351A1 (en) 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
AU2008302295B2 (en) 2007-09-18 2013-11-28 Stanford University Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection
WO2010107742A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
KR100925176B1 (ko) 2007-09-21 2009-11-05 한국전자통신연구원 지리 정보를 이용한 네트워크 상태 표시장치 및 방법
WO2009105507A2 (en) * 2008-02-19 2009-08-27 Adolor Corporation Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
CA2719373A1 (en) 2008-04-16 2009-10-22 Arena Pharmaceuticals, Inc. Processes useful for the synthesis of (r)-1-{2-[4'-(3-methoxypropane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine
DK2307035T3 (da) 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
WO2010039195A2 (en) 2008-09-23 2010-04-08 The Board Of Trustees Of The Leland Stanford Junior University Screening for inhibitors of hcv amphipathic helix (ah) function
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
JP5656980B2 (ja) 2009-05-13 2015-01-21 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー含有の置換芳香族トリアジン化合物
EP2491033A4 (en) 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
US20150313913A1 (en) * 2013-02-05 2015-11-05 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3035926B1 (en) * 2013-08-19 2020-07-29 The Regents of The University of California Compounds and methods for treating an epileptic disorder
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN104936947B (zh) * 2013-12-27 2017-03-08 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
US20230346750A1 (en) 2023-11-02
HRP20220822T1 (hr) 2022-10-28
RS63426B1 (sr) 2022-08-31
PL3261640T3 (pl) 2022-10-31
CA2977135C (en) 2023-08-22
AU2022203274A1 (en) 2022-06-16
CN107530326B (zh) 2021-09-21
CN107530326A (zh) 2018-01-02
BR112017018297B1 (pt) 2023-12-05
AU2016222804C1 (en) 2021-10-14
US20200147048A1 (en) 2020-05-14
KR20230152844A (ko) 2023-11-03
EP4043016A1 (en) 2022-08-17
EP3261640A1 (en) 2018-01-03
JP6884703B2 (ja) 2021-06-09
KR102385665B1 (ko) 2022-04-14
EP3261640A4 (en) 2018-12-19
US20180028499A1 (en) 2018-02-01
JP2021185148A (ja) 2021-12-09
HUE059559T2 (hu) 2022-12-28
SI3261640T1 (sl) 2022-10-28
KR20170118870A (ko) 2017-10-25
CN113546174A (zh) 2021-10-26
DK3261640T3 (da) 2022-07-11
US10874643B2 (en) 2020-12-29
BR112017018297A2 (pt) 2018-04-17
JP2020143087A (ja) 2020-09-10
EA201992474A2 (ru) 2020-02-28
KR20220048045A (ko) 2022-04-19
EP3632434A1 (en) 2020-04-08
AU2021204261A1 (en) 2021-07-29
WO2016138138A1 (en) 2016-09-01
JP2024009839A (ja) 2024-01-23
JP2022116307A (ja) 2022-08-09
US11648237B2 (en) 2023-05-16
CA3204599A1 (en) 2016-09-01
LT3261640T (lt) 2022-07-11
US20210154171A1 (en) 2021-05-27
CA2977135A1 (en) 2016-09-01
PT3261640T (pt) 2022-07-06
AU2016222804A1 (en) 2017-08-31
JP2018506555A (ja) 2018-03-08
AU2016222804B2 (en) 2021-07-15
ES2920886T3 (es) 2022-08-11
EA201992474A3 (ru) 2020-05-31
AU2021204261B2 (en) 2023-08-10
EP3261640B1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
EA201791882A1 (ru) Агонисты 5ht для лечения нарушений
PH12018501656A1 (en) Methods for using fxr agonists
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
EA201591509A1 (ru) Ингибиторы cdc7
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
BR112016013963A2 (pt) terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
PH12017502237A1 (en) Nuclear receptor modulators
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
HK1243430A1 (zh) 通過施用il-6r拮抗劑治療乾眼病的方法
EA202091873A2 (ru) Способы лечения гипотонии
SG11201912228WA (en) Agents, uses and methods for treatment
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
EA201790373A1 (ru) Способы получения модуляторов toll-подобных рецепторов
SG10201507706UA (en) Method, Apparatus and Network for Multi-Domain Conference Management
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
AU2017249211A1 (en) Methods of treatment with selective CB2 receptor agonists
BR112018072887A2 (pt) método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto
EP3558301A4 (en) METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST